Big Lots is struggling! We delve into the factors behind store closures and layoffs, exploring the impact of inflation and ...

A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

It all fits with President Trump’s practice of blaming his predecessors for the nation’s ills. But the strategy also carries risks.

Half of 2025: Revenues. Total revenues were $9.3 million, up 86% YoY. The first-half year revenues of $17.3 million, 89% of F ...

Amylyx is a high-risk biotech targeting rare diseases with strong cash reserves. Key trials soon may drive a 40% stock upside ...

A special magistrate backed parts of the police union’s pension plan, deepening a contract standoff as Delray Beach officials ...

Hinge Health's strong partnerships, high client retention, and integration with major health plans drive predictable revenue and market expansion. Learn more on HNGE stock here.

Europe's capital has operated without a functioning government while drowning in debt equivalent to a major American city's ...

So from the day this council was sworn in to now, that’s about 700  people less every single day who are spending the night ...

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...